Improvements in both therapy and supportive care have allowed the median overall survival for patients diagnosed with advanced stage follicular lymphoma to exceed 20 years; however, a subset of patients exists with less favorable outcomes. This session will review treatment options for patients with early and advanced stage follicular lymphoma, and address how and when novel agents should be introduced into the paradigm. The focus will be on a “precision approach” to ensure patients are not over- or under-treated.
Jonathan W. Friedberg
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members